Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.

MLA

Lubinga, Solomon J., et al. “Budget Impact of Dostarlimab plus Carboplatin-Paclitaxel for Primary Advanced or Recurrent Endometrial Cancer from a Third-Party US Payer Perspective.” Journal of Medical Economics, vol. 27, no. 1, Jan. 2024, pp. 1212–21. EBSCOhost, https://doi.org/10.1080/13696998.2024.2403278.

APA

Lubinga, S. J., Walder, L., Burton, M., & Shen, Q. (2024). Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective. Journal of Medical Economics, 27(1), 1212–1221. https://doi.org/10.1080/13696998.2024.2403278

Chicago

Lubinga, Solomon J., Lydia Walder, Mark Burton, and Qin Shen. 2024. “Budget Impact of Dostarlimab plus Carboplatin-Paclitaxel for Primary Advanced or Recurrent Endometrial Cancer from a Third-Party US Payer Perspective.” Journal of Medical Economics 27 (1): 1212–21. doi:10.1080/13696998.2024.2403278.